Azitra is an early-stage clinical biopharmaceutical company developing therapies for precision dermatology through engineered proteins and live biotherapeutic products. The company's pipeline focuses on treating rare and common skin diseases using genetically modified strains of *Staphylococcus epidermidis* and recombinant protein therapies. Its lead candidate, ATR-12, is in Phase Ib clinical testing for Netherton syndrome, a rare genetic skin disorder. ATR-04, a modified bacterial strain, is in Phase 1/2 trials for treating papulopustular rash associated with epidermal growth factor receptor inhibitor therapy in cancer patients. ATR-01, an engineered recombinant human filaggrin protein, targets ichthyosis vulgaris, a common inherited dry skin condition.
The company operates with a small team of 12 full-time employees and is headquartered in Branford, Connecticut. Azitra has established a collaboration with Bayer, a major pharmaceutical partner, to support its development efforts. As a clinical-stage company incorporated in Delaware and publicly listed on the NYSE, Azitra has not yet advanced products to commercial revenue generation and operates primarily through research and development activities and partnership arrangements.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-2.25 | $-2.25 | +5.1% | |
| 2024 | $-2.37 | $-2.37 | -29.5% | |
| 2023 | $-1.83 | $-1.83 | — |